← Back to Search

Radiation

SABR for Kidney Cancer

Phase 2

Waitlist Available

Led By Raquibul Hannan, MD, PhD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Metastatic renal cell carcinoma with limited measurable extracranial metastases (Limited metastases, or oligometastases, defined as ≤3 sites of metastasis)

Age ≥ 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 years

Awards & highlights

Study Summary

This trial is testing whether a certain kind of radiation can help extend the amount of time patients with a certain kind of kidney cancer live without their disease getting worse, and whether it can delay the need for systemic therapy.

Who is the study for?

This trial is for adults with kidney cancer that has spread to up to three other body parts, but not the brain. They must have had a recent scan showing this and can't have had certain treatments in the last year. Women who can get pregnant and men must use birth control during and after treatment.Check my eligibility

What is being tested?

The study tests if Stereotactic Ablative Body Radiation (SAbR) can delay the need for systemic therapy by targeting only a few metastatic spots in kidney cancer patients, potentially improving survival without immediately resorting to drugs affecting the whole body.See study design

What are the potential side effects?

While specific side effects are not listed here, SAbR typically may cause fatigue, skin reactions at the treatment site, nausea or discomfort. Serious side effects might include damage to nearby organs or tissues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney cancer has spread to no more than 3 places outside my brain.

Select...

I am 18 years old or older.

Select...

My kidney cancer has been confirmed by a pathology test.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to start of systemic therapy (TTST)

Secondary outcome measures

Acute Coryza

Cancer specific survival (CSS)

Health-related quality of life (HRQOL) EQ-5D

+10 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Stereotactic ablative body radiation (SABR)Experimental Treatment1 Intervention

Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,053,776 Total Patients Enrolled

Raquibul Hannan, MD, PhDPrincipal InvestigatorUniversity of Texas

5 Previous Clinical Trials

93 Total Patients Enrolled

Media Library

Stereotactic ablative body radiation (SABR) (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT02956798 — Phase 2

Renal Cell Carcinoma Clinical Trial 2023: Stereotactic ablative body radiation (SABR) Highlights & Side Effects. Trial Name: NCT02956798 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this experiment still available to participants?

"It appears that clinicaltrials.gov does not list this medical trial as being open for recruitment at the present moment. The listing was originally posted on July 19th 2018 and most recently updated April 13th 2022, indicating a lack of current opportunities for patients to participate in this trial. However, there are approximately 2584 other trials actively recruiting now."

Answered by AI